Literature DB >> 18442197

Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells.

Akemi Imaoka1, Tatsuichiro Shima, Kimitoshi Kato, Shigeaki Mizuno, Toshiki Uehara, Satoshi Matsumoto, Hiromi Setoyama, Taeko Hara, Yoshinori Umesaki.   

Abstract

AIM: To determine the anti-inflammatory activity of probiotic Bifidobacteria in Bifidobacteria-fermented milk (BFM) which is effective against active ulcerative colitis (UC) and exacerbations of UC, and to explore the immunoregulatory mechanisms.
METHODS: Peripheral blood mononuclear cells (PBMNC) from UC patients or HT-29 cells were co-cultured with heat-killed probiotic bacteria or culture supernatant of Bifidobacterium breve strain Yakult (BbrY) or Bifidobacterium bifidum strain Yakult (BbiY) to estimate the amount of IL-10 or IL-8 secreted.
RESULTS: Both strains of probiotic Bifidobacteria contained in the BFM induced IL-10 production in PBMNC from UC patients, though BbrY was more effective than BbiY. Conditioned medium (CM) and DNA of both strains inhibited IL-8 secretion in HT-29 cells stimulated with TNF-alpha, whereas no such effect was observed with heat-killed bacteria. The inhibitory effect of CM derived from BbiY was greater than that of CM derived from BbrY. DNAs of the two strains had a comparable inhibitory activity against the secretion of IL-8. CM of BbiY induced a repression of IL-8 gene expression with a higher expression of IkappaB-zeta mRNA 4 h after culture of HT-29 cells compared to that in the absence of CM.
CONCLUSION: Probiotic Bifidobacterium strains in BFM enhance IL-10 production in PBMNC and inhibit IL-8 secretion in intestinal epithelial cells, suggesting that BFM has anti-inflammatory effects against ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442197      PMCID: PMC2708361          DOI: 10.3748/wjg.14.2511

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative?

Authors:  M Campieri; P Gionchetti
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.

Authors:  K Kato; S Mizuno; Y Umesaki; Y Ishii; M Sugitani; A Imaoka; M Otsuka; O Hasunuma; R Kurihara; A Iwasaki; Y Arakawa
Journal:  Aliment Pharmacol Ther       Date:  2004-11-15       Impact factor: 8.171

4.  VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

Authors:  Rodrigo Bibiloni; Richard N Fedorak; Gerald W Tannock; Karen L Madsen; Paolo Gionchetti; Massimo Campieri; Claudio De Simone; R Balfour Sartor
Journal:  Am J Gastroenterol       Date:  2005-07       Impact factor: 10.864

5.  A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding.

Authors:  Gudrun Totzke; Frank Essmann; Stephan Pohlmann; Charlotte Lindenblatt; Reiner U Jänicke; Klaus Schulze-Osthoff
Journal:  J Biol Chem       Date:  2006-03-02       Impact factor: 5.157

6.  Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.

Authors:  M A Zocco; L Zileri dal Verme; F Cremonini; A C Piscaglia; E C Nista; M Candelli; M Novi; D Rigante; I A Cazzato; V Ojetti; A Armuzzi; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2006-06-01       Impact factor: 8.171

7.  A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease.

Authors:  Henri Braat; Pieter Rottiers; Daniel W Hommes; Nathalie Huyghebaert; Erik Remaut; Jean-Paul Remon; Sander J H van Deventer; Sabine Neirynck; Maikel P Peppelenbosch; Lothar Steidler
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-22       Impact factor: 11.382

8.  Serum proinflammatory cytokines and adhesion molecules in ulcerative colitis.

Authors:  Yasushi Umehara; Masatoshi Kudo; Ryosuke Nakaoka; Toshihiko Kawasaki; Mikio Shiomi
Journal:  Hepatogastroenterology       Date:  2006 Nov-Dec

9.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Authors:  E Furrie; S Macfarlane; A Kennedy; J H Cummings; S V Walsh; D A O'neil; G T Macfarlane
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

10.  Augmentation of anti-influenza virus hemagglutinin antibody production by Peyer's patch cells with Bifidobacterium breve YIT4064.

Authors:  H Yasui; N Nagaoka; K Hayakawa
Journal:  Clin Diagn Lab Immunol       Date:  1994-03
View more
  53 in total

1.  Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Authors:  David Philippe; Laurent Favre; Francis Foata; Oskar Adolfsson; Genevieve Perruisseau-Carrier; Karine Vidal; Gloria Reuteler; Johanna Dayer-Schneider; Christoph Mueller; Stéphanie Blum
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics.

Authors:  Theo S Plantinga; Wendy W C van Maren; Jeroen van Bergenhenegouwen; Marjolijn Hameetman; Stefan Nierkens; Cor Jacobs; Dirk J de Jong; Leo A B Joosten; Belinda van't Land; Johan Garssen; Gosse J Adema; Mihai G Netea
Journal:  Clin Vaccine Immunol       Date:  2011-02-02

3.  Secreted factors from Bifidobacterium animalis subsp. lactis inhibit NF-κB-mediated interleukin-8 gene expression in Caco-2 cells.

Authors:  Zhonggui Wang; Jinfeng Wang; Yi Cheng; Xin Liu; Ying Huang
Journal:  Appl Environ Microbiol       Date:  2011-09-16       Impact factor: 4.792

4.  A Probiotic for Ulcerative Colitis: The Culture Wars Continue.

Authors:  Bincy P Abraham; Eamonn M M Quigley
Journal:  Dig Dis Sci       Date:  2018-07       Impact factor: 3.199

5.  Innate immunity and inflammatory bowel disease: a review of clinical evidence and future application.

Authors:  Kyoko Katakura; Hiroshi Watanabe; Hiromasa Ohira
Journal:  Clin J Gastroenterol       Date:  2013-11-22

6.  Moxibustion treatment modulates the gut microbiota and immune function in a dextran sulphate sodium-induced colitis rat model.

Authors:  Qin Qi; Ya-Nan Liu; Xiao-Ming Jin; Lin-Shuang Zhang; Cun Wang; Chun-Hui Bao; Hui-Rong Liu; Huan-Gan Wu; Xiao-Mei Wang
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 7.  Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies.

Authors:  Lauren E Hudson; Sarah E Anderson; Anita H Corbett; Tracey J Lamb
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 8.  Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.

Authors:  Julio Plaza-Diaz; Carolina Gomez-Llorente; Luis Fontana; Angel Gil
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

9.  A two-component regulatory system controls autoregulated serpin expression in Bifidobacterium breve UCC2003.

Authors:  Pablo Alvarez-Martin; Mary O'Connell Motherway; Francesca Turroni; Elena Foroni; Marco Ventura; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2012-07-27       Impact factor: 4.792

Review 10.  Commensal bacteria, traditional and opportunistic pathogens, dysbiosis and bacterial killing in inflammatory bowel diseases.

Authors:  Christopher D Packey; R Balfour Sartor
Journal:  Curr Opin Infect Dis       Date:  2009-06       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.